The National Immunotherapy Cancer (EIN 223067246) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1990

Legal Domicile

Principal Officer

ROBERT A FACCHINA

Phone

9087882200

Tax Period

2023-01-01 to 2023-12-31

The National Immunotherapy Cancer, founded in 1990, is a small nonprofit in the Medical Research sector that reported $151K in total revenue in fiscal year 2023. Revenue surged 3324% from the prior year, signaling strong growth momentum. The organization ran a surplus of $53K, a strong 35% operating margin.

Mission

TO PROVIDE GRANTS TO SECTION 501(C)(3) ORGANIZATIONS THAT ADVANCE AND IMPROVE SCIENTIFIC RESEARCH IN IMMUNOTHERAPY AND TO ORGANIZATIONS THAT PROMOTE, ADVANCE AND IMPROVE EDUCATION AND SUPPORT CANCER PATIENTS

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $161,608

Program Service Revenue $0

Investment Income $13,864

Other Revenue $-24,012

TOTAL REVENUE $151,460

Expense Breakdown

Grants Paid $55,000

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $55,000

Other Expenses $43,040

TOTAL EXPENSES $98,040

Year-over-Year Comparison

	2023	2022	Change
Revenue	$151,460	$4,423	+33.2%
Expenses	$98,040	$136,357	-0.3%
Net Income	$53,420	$-131,934	-1.4%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
DON GRIFFIN	Director	1.00	Director	$0	$0	$0
LAURA JOHNSON	Director	1.00	Director	$0	$0	$0
ROBERT A FACCHINA	President	1.00	Officer	$0	$0	$0
JEFFREY A WEST	Treasurer	1.00	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$151,460	$98,040	$1,051,896	$53,420
2022	$4,423	$136,357	$1,104,751	$-131,934
2021	$6,004	$77,669	$1,361,131	$-71,665
2020	$13,978	$1,023,158	$1,557,796	$-1,009,180
2019	$330,414	$32,577	$1,728,276	$297,837
2018	$328,141	$29,367	$1,566,353	$298,774

The National Immunotherapy Cancer